1. Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial. (December 2020) Authors: Ray, K.K.; Kallend, D.; Leiter, L.A.; Raal, F.J.; Koenig, W.; Jaros, M.J.; Schwartz, G.G.; Landmesser, U.; Wijngaard, P.L.; Wright, R.S.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of inclisiran on haematological and immunological biomarkers: A Pooled analysis of ORION-9, -10 and -11 trial data. (August 2021) Authors: Landmesser, U.; Conde, L. Garcia; Wright, R.S.; Raal, F.J.; Koenig, W.; Leiter, L.A.; Schwartz, G.G.; Kallend, D.G.; Lawrence, D.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials. (August 2019) Authors: Willeit, P.; Ridker, P.; Nestel, P.J.; Simes, J.; Tonkin, A.M.; Pedersen, T.R.; Schwartz, G.G.; Olsson, A.G.; Colhoun, H.M.; Kronenberg, F.; Drechsler, C.; Wanner, C.; Mora, S.; Lesogor, A.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗